Archived explainer. For the current picture see today's RGEN page.
REPLIGEN CORP (RGEN) is down -5.84% in the latest session. Our newswire has captured 1 story on RGEN across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
RGEN stock fell 5.84% to $136.99 in morning trading as one news story from the last 36 hours highlighted Repligen’s plan to acquire BioLife Solutions. The move expands the company’s cell therapy capabilities but appears to have triggered a short-term sell-off, despite multiple recent analyst upgrades and a positive 30-day average sentiment of 51 out of 100, which has improved to 68 in the last seven days.
Repligen announced it will acquire BioLife Solutions, a market-leading biopreservation media company, to enhance its cell therapy offerings. The acquisition is expected to fast-track Repligen’s leadership in the high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business. This strategic move was the only newswire story in the last 36 hours and is the primary driver of the stock’s decline. Despite this, the stock has seen recent analyst activity, including a Benchmark upgrade to Buy with a $185 price target and an Evercore ISI Group Outperform rating with a raised price target of $160. HSBC maintains a Buy rating but lowered its price target to $150, while Wolfe Research initiated coverage at Outperform with a $145 price target.
RGEN has a market cap of $8.3 billion and a P/E ratio of 159.9. The stock is trading within its 52-week range of $100.99 to $175.77. Revenue has grown 17.4% in the trailing twelve months, with a net margin of 6.7%. The stock has a beta of 1.06, indicating moderate volatility. Recent insider transactions include two sales by CFO Jason K. Garland totaling $186,000. Additionally, former President Donald J. Trump sold between $1,001 and $15,000 in RGEN shares on May 22, 2026.
Investors should monitor the stock for any follow-up analyst commentary or earnings updates. No earnings date is currently provided, but coverage breadth and price target adjustments may offer further insight.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business
More on RGEN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RGEN move explainers: 2026-07-29 · 2026-07-28 · 2026-07-22